Tumor characteristics and tumor directed treatment in patients with tumor overgrowth related aero-digestive fistulas (ADF)
| n (%) . | . | |
|---|---|---|
| Clinical tumor stage | ||
| T1 | 0 (0) | |
| T2 | 1 (3.0) | |
| T3 | 6 (18.2) | |
| T4 | 23 (69.7) | |
| Missing | 3 | |
| Clinical nodal stage | ||
| N0 | 6 (18.2) | |
| N1 | 9 (27.3) | |
| N2 | 8 (24.2) | |
| N3 | 7 (21.2) | |
| Missing | 3 | |
| Distant metastasis | ||
| Yes | 7 (21.2) | |
| No | 23 (69.7) | |
| Missing | 3 | |
| Primary tumor location | ||
| Proximal | 6 (18.2) | |
| Middle | 16 (48.5) | |
| Distal | 4 (12.1) | |
| Gastroesophageal junction | 1 (3.0) | |
| Non esophageal cancer | 6 (18.2) | |
| Missing | 0 | |
| Histology | ||
| Esophageal squamous cell carcinoma | 22 (66.7) | |
| Esophageal adenocarcinoma | 3 (9.1) | |
| Small cell lung carcinoma | 1 (3.0) | |
| Neuroendocrine tumor | 1 (3.0) | |
| Mesothelioma | 1 (3.0) | |
| Lymphoma | 1 (3.0) | |
| Missing | 4 | |
| Tumor directed treatment | ||
| Neoadjuvant chemotherapy | 0 (0) | |
| Palliative chemotherapy | 4 (12.1) | |
| Neoadjuvant chemoradiotherapy | 5 (15.2) | |
| Definitive chemoradiotherapy | 17 (51.5) | |
| None | 7 (21.2) | |
| Missing | 0 | |
| n (%) . | . | |
|---|---|---|
| Clinical tumor stage | ||
| T1 | 0 (0) | |
| T2 | 1 (3.0) | |
| T3 | 6 (18.2) | |
| T4 | 23 (69.7) | |
| Missing | 3 | |
| Clinical nodal stage | ||
| N0 | 6 (18.2) | |
| N1 | 9 (27.3) | |
| N2 | 8 (24.2) | |
| N3 | 7 (21.2) | |
| Missing | 3 | |
| Distant metastasis | ||
| Yes | 7 (21.2) | |
| No | 23 (69.7) | |
| Missing | 3 | |
| Primary tumor location | ||
| Proximal | 6 (18.2) | |
| Middle | 16 (48.5) | |
| Distal | 4 (12.1) | |
| Gastroesophageal junction | 1 (3.0) | |
| Non esophageal cancer | 6 (18.2) | |
| Missing | 0 | |
| Histology | ||
| Esophageal squamous cell carcinoma | 22 (66.7) | |
| Esophageal adenocarcinoma | 3 (9.1) | |
| Small cell lung carcinoma | 1 (3.0) | |
| Neuroendocrine tumor | 1 (3.0) | |
| Mesothelioma | 1 (3.0) | |
| Lymphoma | 1 (3.0) | |
| Missing | 4 | |
| Tumor directed treatment | ||
| Neoadjuvant chemotherapy | 0 (0) | |
| Palliative chemotherapy | 4 (12.1) | |
| Neoadjuvant chemoradiotherapy | 5 (15.2) | |
| Definitive chemoradiotherapy | 17 (51.5) | |
| None | 7 (21.2) | |
| Missing | 0 | |
Tumor characteristics and tumor directed treatment in patients with tumor overgrowth related aero-digestive fistulas (ADF)
| n (%) . | . | |
|---|---|---|
| Clinical tumor stage | ||
| T1 | 0 (0) | |
| T2 | 1 (3.0) | |
| T3 | 6 (18.2) | |
| T4 | 23 (69.7) | |
| Missing | 3 | |
| Clinical nodal stage | ||
| N0 | 6 (18.2) | |
| N1 | 9 (27.3) | |
| N2 | 8 (24.2) | |
| N3 | 7 (21.2) | |
| Missing | 3 | |
| Distant metastasis | ||
| Yes | 7 (21.2) | |
| No | 23 (69.7) | |
| Missing | 3 | |
| Primary tumor location | ||
| Proximal | 6 (18.2) | |
| Middle | 16 (48.5) | |
| Distal | 4 (12.1) | |
| Gastroesophageal junction | 1 (3.0) | |
| Non esophageal cancer | 6 (18.2) | |
| Missing | 0 | |
| Histology | ||
| Esophageal squamous cell carcinoma | 22 (66.7) | |
| Esophageal adenocarcinoma | 3 (9.1) | |
| Small cell lung carcinoma | 1 (3.0) | |
| Neuroendocrine tumor | 1 (3.0) | |
| Mesothelioma | 1 (3.0) | |
| Lymphoma | 1 (3.0) | |
| Missing | 4 | |
| Tumor directed treatment | ||
| Neoadjuvant chemotherapy | 0 (0) | |
| Palliative chemotherapy | 4 (12.1) | |
| Neoadjuvant chemoradiotherapy | 5 (15.2) | |
| Definitive chemoradiotherapy | 17 (51.5) | |
| None | 7 (21.2) | |
| Missing | 0 | |
| n (%) . | . | |
|---|---|---|
| Clinical tumor stage | ||
| T1 | 0 (0) | |
| T2 | 1 (3.0) | |
| T3 | 6 (18.2) | |
| T4 | 23 (69.7) | |
| Missing | 3 | |
| Clinical nodal stage | ||
| N0 | 6 (18.2) | |
| N1 | 9 (27.3) | |
| N2 | 8 (24.2) | |
| N3 | 7 (21.2) | |
| Missing | 3 | |
| Distant metastasis | ||
| Yes | 7 (21.2) | |
| No | 23 (69.7) | |
| Missing | 3 | |
| Primary tumor location | ||
| Proximal | 6 (18.2) | |
| Middle | 16 (48.5) | |
| Distal | 4 (12.1) | |
| Gastroesophageal junction | 1 (3.0) | |
| Non esophageal cancer | 6 (18.2) | |
| Missing | 0 | |
| Histology | ||
| Esophageal squamous cell carcinoma | 22 (66.7) | |
| Esophageal adenocarcinoma | 3 (9.1) | |
| Small cell lung carcinoma | 1 (3.0) | |
| Neuroendocrine tumor | 1 (3.0) | |
| Mesothelioma | 1 (3.0) | |
| Lymphoma | 1 (3.0) | |
| Missing | 4 | |
| Tumor directed treatment | ||
| Neoadjuvant chemotherapy | 0 (0) | |
| Palliative chemotherapy | 4 (12.1) | |
| Neoadjuvant chemoradiotherapy | 5 (15.2) | |
| Definitive chemoradiotherapy | 17 (51.5) | |
| None | 7 (21.2) | |
| Missing | 0 | |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
